晚期发作的精神病治疗与辅助药物治疗
Irina Boksha1, Olga Savushkina1, Vladimir Sheshenin1
1Mental Health Research Centre, Moscow, Russia.
Frontiers in psychiatry
|January 8, 2024
概括
使用2-乙基-6-甲基-3-基氨酸酸 (EMHS) 的辅助治疗可以通过使生物化学参数正常化,使特定晚发性精神病 (LOP) 患者受益. 这种方法有助于管理LOP,特别是当患者经历标准抗精神病和抗抑郁药治疗的副作用时.
科学领域:
- 神经科学是一个神经科学.
- 精神病学是一个精神病学.
- 生物化学 生物化学
背景情况:
- 晚期发病精神病 (LOP) 是一种辅助药物治疗已经证明可行性的情况.
- 确定从辅助治疗中受益的特定患者子组对于优化LOP治疗至关重要.
- 血液生物化学参数可以作为区分对辅助治疗有反应的患者亚组的指标.
研究的目的:
- 测试假设,某些临床特征和血液生物化学参数可以识别LOP患者,这些患者可以在抗精神病药物和抗抑郁药物一起受益于辅助治疗.
- 评估LOP患者中辅助的2-乙基-6-甲基-3-酸酸盐 (EMHS) 和其他神经保护剂的疗效.
- 探索生物化学标记,临床结果和LOP中的治疗反应之间的关系.
主要方法:
- 在实际的临床实践中,对59名LOP患者接受抗精神病药物和抗抑郁药物的队列进行了跟踪.
- 收集的数据包括人口统计和临床信息 (PANSS,CDSS,CGI-S,HAMD-17分数),治疗细节,不良反应和血液生物化学参数 (谷氨酸和谷氨代谢酶).
- 根据辅助治疗,患者被分为三个组:没有辅助治疗 (Gr1),EMHS (Gr2) 和其他神经保护药物 (Gr3). 一个匹配的对照组被纳入用于比较.
主要成果:
- 与对照组相比,所有LOP患者组都显示了红细胞谷氨还原酶活性降低.
- 接受EMHS (Gr2) 治疗的患者表现出基线谷氨酸脱酶和谷氨-S转移酶活动显著下降,这些活动在治疗后恢复正常,以达到对照水平.
- 与Gr1不同,Gr2在治疗后显示出改善的生物化学参数,这表明EMHS在正常化新陈代谢和潜在预测治疗反应方面的有效性.
结论:
- 辅助神经保护药物,特别是EMHS,在特定的LOP患者亚组中是有效的,特别是那些患有心理药物治疗显著副作用的患者.
- 在EMHS治疗小组中,生物化学参数的正常化以控制范围支持其在LOP患者代谢正常化中的作用.
- 特定的临床标准和生化标志物可以指导对LOP患者的辅助EMHS治疗的处方,从而有可能提高治疗疗效.
相关概念视频
01:26Psychosis: Goals of Pharmacotherapy
133
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
133
01:28Psychosis and Antipsychotic Drugs: Overview
263
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
263
01:28Drug Therapy
45
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
45
01:24Mania and Antimanic Drugs: Overview
184
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
184
01:23Antidepressant Drugs: MAOIs and Other Agents
237
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
237
01:24Parkinson's Disease: Treatment
272
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
272